Rat Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
416€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Rat Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx694327
tested applications
SDS-PAGE
Description
Rat Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein is a recombinant Rat protein expressed in HEK293 cells.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Host | HEK293 cells |
| Origin | Rat |
| Observed MW | Molecular Weight: Calculated MW: 75.9 kDa Observed MW (SDS-PAGE): 60 kDa Sequence Fragment: Met1-Gln691 Tag: C-terminal His tag |
| Expression | Recombinant |
| Purity | >95% (SDS-PAGE) |
| Size 1 | 20 µg |
| Size 2 | 100 µg |
| Form | Lyophilized Reconstitute in sterile H2O. Do not vortex. |
| Tested Applications | SDS-PAGE |
| Buffer | Prior to lyophilization: PBS, pH 7.4, containing 5% - 8% Trehalose, Mannitol and 0.01% Tween-80. |
| Availability | Shipped within 5-15 working days. |
| Storage | Store lyophilized between -20 °C and -80 °C. |
| Dry Ice | No |
| UniProt ID | P59996 |
| Gene ID | 298296 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Protein PCSK9 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Related Products
Guinea pig PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit
Ver Producto
Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA Kit
Ver Producto